316 related articles for article (PubMed ID: 31451044)
1. Fecal DNA Testing for Colorectal Cancer Screening.
Carethers JM
Annu Rev Med; 2020 Jan; 71():59-69. PubMed ID: 31451044
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
3. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
Pickhardt PJ; Correale L; Hassan C
AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
[No Abstract] [Full Text] [Related]
4. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.
Bosch LJW; Melotte V; Mongera S; Daenen KLJ; Coupé VMH; van Turenhout ST; Stoop EM; de Wijkerslooth TR; Mulder CJJ; Rausch C; Kuipers EJ; Dekker E; Domanico MJ; Lidgard GP; Berger BM; van Engeland M; Carvalho B; Meijer GA
Am J Gastroenterol; 2019 Dec; 114(12):1909-1918. PubMed ID: 31764091
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
6. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
Prince M; Lester L; Chiniwala R; Berger B
World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
[TBL] [Abstract][Full Text] [Related]
7. A novel multitarget stool DNA test for colorectal cancer screening.
Malik P
Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
9. Performance of multitarget stool DNA testing in African American patients.
Cooper GS; Markowitz SD; Chen Z; Tuck M; Willis JE; Berger BM; Brenner DE; Li L
Cancer; 2018 Oct; 124(19):3876-3880. PubMed ID: 30193399
[TBL] [Abstract][Full Text] [Related]
10. Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People.
Redwood DG; Asay ED; Blake ID; Sacco PE; Christensen CM; Sacco FD; Tiesinga JJ; Devens ME; Alberts SR; Mahoney DW; Yab TC; Foote PH; Smyrk TC; Provost EM; Ahlquist DA
Mayo Clin Proc; 2016 Jan; 91(1):61-70. PubMed ID: 26520415
[TBL] [Abstract][Full Text] [Related]
11. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening.
Johnson DH; Kisiel JB; Burger KN; Mahoney DW; Devens ME; Ahlquist DA; Sweetser S
Gastrointest Endosc; 2017 Mar; 85(3):657-665.e1. PubMed ID: 27884518
[TBL] [Abstract][Full Text] [Related]
12. Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study.
Imperiale TF; Kisiel JB; Itzkowitz SH; Scheu B; Duimstra EK; Statz S; Berger BM; Limburg PJ
Cancer Prev Res (Phila); 2021 Apr; 14(4):489-496. PubMed ID: 33436397
[TBL] [Abstract][Full Text] [Related]
13. Multitarget stool DNA testing for colorectal-cancer screening.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
[TBL] [Abstract][Full Text] [Related]
14. Colonoscopy Findings in FIT+ and mt-sDNA+ Patients versus in Colonoscopy-only Patients: New Hampshire Colonoscopy Registry Data.
Anderson JC; Robinson CM; Hisey W; Limburg PJ; Butterly LF
Cancer Prev Res (Phila); 2022 Jul; 15(7):455-464. PubMed ID: 35378546
[TBL] [Abstract][Full Text] [Related]
15. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT).
Heigh RI; Yab TC; Taylor WR; Hussain FT; Smyrk TC; Mahoney DW; Domanico MJ; Berger BM; Lidgard GP; Ahlquist DA
PLoS One; 2014; 9(1):e85659. PubMed ID: 24465639
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive fecal testing for colorectal cancer.
Zou J; Xiao Z; Wu Y; Yang J; Cui N
Clin Chim Acta; 2022 Jan; 524():123-131. PubMed ID: 34756863
[TBL] [Abstract][Full Text] [Related]
17. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
18. Detection of High-Risk Sessile Serrated Lesions: Multitarget Stool DNA Versus CT Colonography.
Deiss-Yehiely N; Graffy PM; Weigman B; Hassan C; Matkowskyj KA; Pickhardt PJ; Weiss JM
AJR Am J Roentgenol; 2022 Apr; 218(4):670-676. PubMed ID: 34755523
[No Abstract] [Full Text] [Related]
19. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
